Prime Medicine, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Prime Medicine, Inc. (PRME) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.55 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.59, a 49.58% increase year-over-year.
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.40, a 70.84% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $8.23, a 34.05% decline year-over-year.
- Prime Medicine, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $12.48.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month |
|---|---|---|---|
| 2026-06-30 | $3.55 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $3.59 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $1.95 10-Q · filed 2025-11-07 | ||
| 2025-06-30 | $1.94 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $2.40 10-Q · filed 2025-05-08 | ||
| 2024-09-30 | $8.03 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | $8.16 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | $8.23 10-Q · filed 2024-05-10 | ||
| 2023-09-30 | $12.87 10-Q · filed 2023-11-03 | ||
| 2023-06-30 | $12.76 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $12.48 10-Q · filed 2023-05-11 | ||
| 2022-09-30 | $8.40 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |